ONC-CHAT: Dr. Martine Piccart, 'Absolutely No Advantage' to 2 Years of Trastuzumab
December 11, 2012|Oncology Practice
Author and Disclosure Information
Eight-year follow-up data from the HERA trial confirm that one-year of adjuvant trastuzumab (Herceptin) is better than 2 years -- or none in HER2-positive breast cancer. Bruce Jancin of IMNG Medical Media interviews Dr. Martine Piccart at the San Antonio Breast Cancer Symposium, where she presented encouraging results from this large multinational effort.